Keyword Analysis & Research: emergent biosolutions

Keyword Analysis


Keyword CPC PCC Volume Score Length of keyword
emergent biosolutions0.280.535901821
emergent0.060.95311928
biosolutions1.86159494012

Keyword Research: People who searched emergent biosolutions also searched

Keyword CPC PCC Volume Score
emergent biosolutions0.620.6693841

Search Results related to emergent biosolutions on Search Engine

  • Emergent BioSolutions – Global Specialty Life Sciences Company

    emergentbiosolutions.com

    https://www.emergentbiosolutions.com/

    WebBioservices. Emergent offers molecule-to-market drug substance and drug product development and manufacturing services to biopharma innovators, government, and non-government organizations. At Emergent, our mission is to protect and enhance life. View our 2023 Annual Report.

    DA: 59 PA: 60 MOZ Rank: 24

  • About Us – Emergent BioSolutions

    emergentbiosolutions.com

    https://www.emergentbiosolutions.com/about-us/

    WebAt Emergent, we develop, manufacture, and deliver protections against public health threats through a pipeline of innovative vaccines and therapeutics worldwide. For 25 years, we’ve been at work defending people from things we hope will never happen—so that we’re prepared, just in case they ever do.

    DA: 16 PA: 37 MOZ Rank: 44

  • Emergent BioSolutions to Release First Quarter 2024 Financial …

    emergentbiosolutions.com

    https://investors.emergentbiosolutions.com/news-releases/news-release-details/emergent-biosolutions-release-first-quarter-2024-financial

    Web3 days ago · GAITHERSBURG, Md., April 22, 2024 (GLOBE NEWSWIRE) -- Emergent BioSolutions Inc. (NYSE: EBS) will host a conference call on Wednesday, May 1, 2024, at 5:00 pm eastern time to discuss the financial results for the first quarter 2024, key business updates, revenue guidance for the second quarter of 2024, and financial outlook for full …

    DA: 52 PA: 49 MOZ Rank: 2

  • Emergent BioSolutions - Wikipedia

    wikipedia.org

    https://en.wikipedia.org/wiki/Emergent_BioSolutions

    WebEmergent BioSolutions Inc. is an American multinational specialty biopharmaceutical company headquartered in Gaithersburg, Maryland. It develops vaccines and antibody therapeutics for infectious diseases and opioid overdoses, and it provides medical devices for biodefense purposes.

    DA: 37 PA: 50 MOZ Rank: 17

  • Investors | Emergent BioSolutions Inc.

    emergentbiosolutions.com

    https://investors.emergentbiosolutions.com/

    WebMar 6, 2024 · Emergent BioSolutions Reports Fourth Quarter 2023 Financial Results. Fourth Quarter 2023 Total Revenues of $277 million , which aligned our Full Year to the mid-point of guidance Full Year 2023 Total Revenues of $1 .05 billion, which was the mid-point of guidance Fourth Quarter 2023 Net. Read More. SEE ALL NEWS RELEASES.

    DA: 86 PA: 60 MOZ Rank: 13

  • Emergent BioSolutions to Release First Quarter 2024 Financial …

    yahoo.com

    https://finance.yahoo.com/news/emergent-biosolutions-release-first-quarter-120500815.html

    Web2 days ago · GAITHERSBURG, Md., April 22, 2024 (GLOBE NEWSWIRE) -- Emergent BioSolutions Inc. (NYSE: EBS) will host a conference call on Wednesday, May 1, 2024, at 5:00 pm eastern time to discuss the financial ...

    DA: 41 PA: 45 MOZ Rank: 6

  • About Us - emergentbio.com

    emergentbio.com

    https://emergentbio.com/about-us

    WebEmergent BioSolutions specializes in confronting — and combating — the most serious intentional and natural threats to public health, including anthrax, Ebola, smallpox, botulism, and opioid addiction. The company has been proud to serve as a leading provider of antiviral, antimicrobial, and hyperimmune products for the United States and a ...

    DA: 56 PA: 18 MOZ Rank: 86

  • Emergent BioSolutions Announces Growth Strategy and 2024 …

    emergentbiosolutions.com

    https://www.emergentbiosolutions.com/press/news-release-details-emergent-biosolutions-announces-growth-strategy-and-2024-goals/

    WebCompany aspires to exceed $2 billion in revenue with 27%-30% adjusted EBITDA margin by year end 2024. GAITHERSBURG, Md., Nov. 21, 2019 (GLOBE NEWSWIRE) — Emergent BioSolutions Inc. (NYSE: EBS) today outlined its growth strategy over the next five years and announced its 2024 financial and operational goals during the company’s Analyst and ...

    DA: 43 PA: 39 MOZ Rank: 9

  • News – Emergent BioSolutions

    emergentbiosolutions.com

    https://www.emergentbiosolutions.com/news-releases/

    WebNew Data Presented at ISPOR 2022 Analyzes the Real-world Economic Burden of Prescription Opioid Overdose and Use of Naloxone in the United States Using a Large Healthcare Claims Database As ... Read More.

    DA: 14 PA: 24 MOZ Rank: 47

  • Press Releases – Emergent BioSolutions

    emergentbiosolutions.com

    https://www.emergentbiosolutions.com/press-releases/

    WebEmergent BioSolutions Reports Financial Results for Fourth Quarter 2021 Reports Q4 2021 total revenues of $723M and Adjusted EBITDA of $348M resulting in FY 2021 total revenues of $1,793M and... Read More

    DA: 62 PA: 27 MOZ Rank: 76